Brad Poore

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Amira Elgogary, Qingguo Xu, Brad Poore et al. · Proceedings of the National Academy of Sciences · 2016 · 231 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources

AeRyon Kim, Isamu Z. Hartman, Brad Poore et al. · Nature Communications · 2014 · 67 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold

Sarah C. Zimmermann, Emily F. Wolf, Andrew Luu et al. · ACS Medicinal Chemistry Letters · 2016 · 65 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine

Sabrina Wang, Brad Poore, Jesse Alt et al. · Clinical Cancer Research · 2019 · 34 citations · Full text

Medicine, Biochemistry, Oncology +17

Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin

Brad Poore, Ming Yuan, Antje Arnold et al. · Neuro-Oncology · 2018 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17